Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
Although an androgen deprivation therapy plus docetaxel regimen was shown to extend the survival of some patients with metastatic hormone-sensitive prostate cancer compared with androgen deprivation therapy alone, currently, there is no report in the literature investigating the impact of upfront do...
Gespeichert in:
| Veröffentlicht in: | Clinical genitourinary cancer 2018-04, Vol.16 (2), p.130-134 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 134 |
|---|---|
| container_issue | 2 |
| container_start_page | 130 |
| container_title | Clinical genitourinary cancer |
| container_volume | 16 |
| creator | Francini, Edoardo Yip, Steven Ahmed, Shubidito Li, Haocheng Ardolino, Luke Evan, Carolyn P. Kaymakcalan, Marina Shaw, Grace K. Kantoff, Philip W. Taplin, Mary-Ellen Alimohamed, Nimira S. Joshua, Anthony M. Heng, Daniel Y.C. Sweeney, Christopher J. |
| description | Although an androgen deprivation therapy plus docetaxel regimen was shown to extend the survival of some patients with metastatic hormone-sensitive prostate cancer compared with androgen deprivation therapy alone, currently, there is no report in the literature investigating the impact of upfront docetaxel on subsequent first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer. This study showed that their activity is maintained regardless of previous use of docetaxel for metastatic hormone-sensitive prostate cancer. These findings can aid treatment decision-making.
The CHAARTED (ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) and STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent therapies is still unexplored. As abiraterone acetate (AA) and enzalutamide (E) are the most commonly used first-line treatment for metastatic castration-resistant prostate cancer (mCRPC), we aimed to assess whether they maintained their efficacy after ADT+D versus ADT alone.
A cohort of patients with mCRPC treated between 2014 and 2017 with first-line AA or E for mCRPC was identified from 3 hospitals’ institutional review board-approved databases. Patients were classified by use of D for mHSPC. This time frame was chosen as ADT+D became a valid therapeutic option for mHSPC in 2014, and it inherently entailed a short follow-up time on AA/E. The endpoints included overall survival from ADT start, overall survival from AA/E start, and time to AA/E start from ADT start. Differences between groups were assessed using the log-rank test.
Of the 102 patients with mCRPC identified, 50 (49%) had previously received ADT alone, while 52 (51%) had ADT+D. No statistically significant difference in any of the evaluated outcomes was observed between the 2 cohorts. Yet, deaths in the ADT+D group were 12 versus 21 in the ADT alone, after a median follow-up of 24.4 and 29.8 months, respectively.
In a cohort of ADT/ADT+D-treated patients with mCRPC with short times to first-line AA/E and follow-up, the efficacy of AA/E is similar regardless of previous use of D. |
| doi_str_mv | 10.1016/j.clgc.2017.12.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5986287</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1558767317303981</els_id><sourcerecordid>1989592559</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4362-f11f1951ca42e6603c2c6d5d5c01f467e2115a07b58f0074faddae6f15f3fd23</originalsourceid><addsrcrecordid>eNp9Uttu1DAQjRCIXuAHeEB-REIJHmedi4SQomxLkYrKw75bXme89SqxFztZtXwN38K_9D9wuqWCPvBij2bmnDMzOknyBmgGFIoP20z1G5UxCmUGLKPAniXHUOdVSouKPY8x51VaFmV-lJyEsKV0waGkL5MjVuc55BUcJ3dtb6xRsidX06jcgIE4Tc6ND2MaK0iatfFyRO_mWOEYY-I8ObM_ZD-NcjAdEh0TX2MpxKpRpI1BxBhnU4_BxKwdyTfvwj24lVahJ40e59d23m3QkiXuvNnfg8jqGr3c3f76-Z4s3Sx5g_2s2SxXpOnnQZ4IXjg_xHQa0AYzmj0-VXuVvNCyD_j64T9NVudnq_Yivbz6_KVtLlO1yAuWagANNQclFwyLguaKqaLjHVcU9KIokQFwScs1rzSl5ULLrpNYaOA61x3LT5NPB9rdtB6wU2jjHXoRNxukvxVOGvFvxZprsXF7weuqYFUZCd49EHj3fcIwisEEhX0vLbopCKirmteM8zq2skOriqsGj_pRBqiY7SG2YraHmO0hgIlojwh6-_eAj5A_fogNHw8NGK-0N-hFUAbjCTvjUY2ic-Z__L8B7yjThg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1989592559</pqid></control><display><type>article</type><title>Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Francini, Edoardo ; Yip, Steven ; Ahmed, Shubidito ; Li, Haocheng ; Ardolino, Luke ; Evan, Carolyn P. ; Kaymakcalan, Marina ; Shaw, Grace K. ; Kantoff, Philip W. ; Taplin, Mary-Ellen ; Alimohamed, Nimira S. ; Joshua, Anthony M. ; Heng, Daniel Y.C. ; Sweeney, Christopher J.</creator><creatorcontrib>Francini, Edoardo ; Yip, Steven ; Ahmed, Shubidito ; Li, Haocheng ; Ardolino, Luke ; Evan, Carolyn P. ; Kaymakcalan, Marina ; Shaw, Grace K. ; Kantoff, Philip W. ; Taplin, Mary-Ellen ; Alimohamed, Nimira S. ; Joshua, Anthony M. ; Heng, Daniel Y.C. ; Sweeney, Christopher J.</creatorcontrib><description>Although an androgen deprivation therapy plus docetaxel regimen was shown to extend the survival of some patients with metastatic hormone-sensitive prostate cancer compared with androgen deprivation therapy alone, currently, there is no report in the literature investigating the impact of upfront docetaxel on subsequent first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer. This study showed that their activity is maintained regardless of previous use of docetaxel for metastatic hormone-sensitive prostate cancer. These findings can aid treatment decision-making.
The CHAARTED (ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) and STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent therapies is still unexplored. As abiraterone acetate (AA) and enzalutamide (E) are the most commonly used first-line treatment for metastatic castration-resistant prostate cancer (mCRPC), we aimed to assess whether they maintained their efficacy after ADT+D versus ADT alone.
A cohort of patients with mCRPC treated between 2014 and 2017 with first-line AA or E for mCRPC was identified from 3 hospitals’ institutional review board-approved databases. Patients were classified by use of D for mHSPC. This time frame was chosen as ADT+D became a valid therapeutic option for mHSPC in 2014, and it inherently entailed a short follow-up time on AA/E. The endpoints included overall survival from ADT start, overall survival from AA/E start, and time to AA/E start from ADT start. Differences between groups were assessed using the log-rank test.
Of the 102 patients with mCRPC identified, 50 (49%) had previously received ADT alone, while 52 (51%) had ADT+D. No statistically significant difference in any of the evaluated outcomes was observed between the 2 cohorts. Yet, deaths in the ADT+D group were 12 versus 21 in the ADT alone, after a median follow-up of 24.4 and 29.8 months, respectively.
In a cohort of ADT/ADT+D-treated patients with mCRPC with short times to first-line AA/E and follow-up, the efficacy of AA/E is similar regardless of previous use of D.</description><identifier>ISSN: 1558-7673</identifier><identifier>EISSN: 1938-0682</identifier><identifier>DOI: 10.1016/j.clgc.2017.12.012</identifier><identifier>PMID: 29331381</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Abiraterone Acetate - administration & dosage ; Abiraterone Acetate - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; AR targeting agents ; Benzamides ; CHAARTED ; Disease-Free Survival ; Docetaxel - administration & dosage ; Docetaxel - therapeutic use ; Humans ; Male ; mCRPC ; mCRPC sequencing ; mHSPC ; Nitriles ; Phenylthiohydantoin - administration & dosage ; Phenylthiohydantoin - analogs & derivatives ; Phenylthiohydantoin - therapeutic use ; Prostatic Neoplasms, Castration-Resistant - drug therapy ; Retrospective Studies ; Survival Analysis ; Treatment Outcome</subject><ispartof>Clinical genitourinary cancer, 2018-04, Vol.16 (2), p.130-134</ispartof><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4362-f11f1951ca42e6603c2c6d5d5c01f467e2115a07b58f0074faddae6f15f3fd23</citedby><cites>FETCH-LOGICAL-c4362-f11f1951ca42e6603c2c6d5d5c01f467e2115a07b58f0074faddae6f15f3fd23</cites><orcidid>0000-0003-4270-7023</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29331381$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Francini, Edoardo</creatorcontrib><creatorcontrib>Yip, Steven</creatorcontrib><creatorcontrib>Ahmed, Shubidito</creatorcontrib><creatorcontrib>Li, Haocheng</creatorcontrib><creatorcontrib>Ardolino, Luke</creatorcontrib><creatorcontrib>Evan, Carolyn P.</creatorcontrib><creatorcontrib>Kaymakcalan, Marina</creatorcontrib><creatorcontrib>Shaw, Grace K.</creatorcontrib><creatorcontrib>Kantoff, Philip W.</creatorcontrib><creatorcontrib>Taplin, Mary-Ellen</creatorcontrib><creatorcontrib>Alimohamed, Nimira S.</creatorcontrib><creatorcontrib>Joshua, Anthony M.</creatorcontrib><creatorcontrib>Heng, Daniel Y.C.</creatorcontrib><creatorcontrib>Sweeney, Christopher J.</creatorcontrib><title>Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer</title><title>Clinical genitourinary cancer</title><addtitle>Clin Genitourin Cancer</addtitle><description>Although an androgen deprivation therapy plus docetaxel regimen was shown to extend the survival of some patients with metastatic hormone-sensitive prostate cancer compared with androgen deprivation therapy alone, currently, there is no report in the literature investigating the impact of upfront docetaxel on subsequent first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer. This study showed that their activity is maintained regardless of previous use of docetaxel for metastatic hormone-sensitive prostate cancer. These findings can aid treatment decision-making.
The CHAARTED (ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) and STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent therapies is still unexplored. As abiraterone acetate (AA) and enzalutamide (E) are the most commonly used first-line treatment for metastatic castration-resistant prostate cancer (mCRPC), we aimed to assess whether they maintained their efficacy after ADT+D versus ADT alone.
A cohort of patients with mCRPC treated between 2014 and 2017 with first-line AA or E for mCRPC was identified from 3 hospitals’ institutional review board-approved databases. Patients were classified by use of D for mHSPC. This time frame was chosen as ADT+D became a valid therapeutic option for mHSPC in 2014, and it inherently entailed a short follow-up time on AA/E. The endpoints included overall survival from ADT start, overall survival from AA/E start, and time to AA/E start from ADT start. Differences between groups were assessed using the log-rank test.
Of the 102 patients with mCRPC identified, 50 (49%) had previously received ADT alone, while 52 (51%) had ADT+D. No statistically significant difference in any of the evaluated outcomes was observed between the 2 cohorts. Yet, deaths in the ADT+D group were 12 versus 21 in the ADT alone, after a median follow-up of 24.4 and 29.8 months, respectively.
In a cohort of ADT/ADT+D-treated patients with mCRPC with short times to first-line AA/E and follow-up, the efficacy of AA/E is similar regardless of previous use of D.</description><subject>Abiraterone Acetate - administration & dosage</subject><subject>Abiraterone Acetate - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>AR targeting agents</subject><subject>Benzamides</subject><subject>CHAARTED</subject><subject>Disease-Free Survival</subject><subject>Docetaxel - administration & dosage</subject><subject>Docetaxel - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>mCRPC</subject><subject>mCRPC sequencing</subject><subject>mHSPC</subject><subject>Nitriles</subject><subject>Phenylthiohydantoin - administration & dosage</subject><subject>Phenylthiohydantoin - analogs & derivatives</subject><subject>Phenylthiohydantoin - therapeutic use</subject><subject>Prostatic Neoplasms, Castration-Resistant - drug therapy</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>1558-7673</issn><issn>1938-0682</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Uttu1DAQjRCIXuAHeEB-REIJHmedi4SQomxLkYrKw75bXme89SqxFztZtXwN38K_9D9wuqWCPvBij2bmnDMzOknyBmgGFIoP20z1G5UxCmUGLKPAniXHUOdVSouKPY8x51VaFmV-lJyEsKV0waGkL5MjVuc55BUcJ3dtb6xRsidX06jcgIE4Tc6ND2MaK0iatfFyRO_mWOEYY-I8ObM_ZD-NcjAdEh0TX2MpxKpRpI1BxBhnU4_BxKwdyTfvwj24lVahJ40e59d23m3QkiXuvNnfg8jqGr3c3f76-Z4s3Sx5g_2s2SxXpOnnQZ4IXjg_xHQa0AYzmj0-VXuVvNCyD_j64T9NVudnq_Yivbz6_KVtLlO1yAuWagANNQclFwyLguaKqaLjHVcU9KIokQFwScs1rzSl5ULLrpNYaOA61x3LT5NPB9rdtB6wU2jjHXoRNxukvxVOGvFvxZprsXF7weuqYFUZCd49EHj3fcIwisEEhX0vLbopCKirmteM8zq2skOriqsGj_pRBqiY7SG2YraHmO0hgIlojwh6-_eAj5A_fogNHw8NGK-0N-hFUAbjCTvjUY2ic-Z__L8B7yjThg</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Francini, Edoardo</creator><creator>Yip, Steven</creator><creator>Ahmed, Shubidito</creator><creator>Li, Haocheng</creator><creator>Ardolino, Luke</creator><creator>Evan, Carolyn P.</creator><creator>Kaymakcalan, Marina</creator><creator>Shaw, Grace K.</creator><creator>Kantoff, Philip W.</creator><creator>Taplin, Mary-Ellen</creator><creator>Alimohamed, Nimira S.</creator><creator>Joshua, Anthony M.</creator><creator>Heng, Daniel Y.C.</creator><creator>Sweeney, Christopher J.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4270-7023</orcidid></search><sort><creationdate>20180401</creationdate><title>Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer</title><author>Francini, Edoardo ; Yip, Steven ; Ahmed, Shubidito ; Li, Haocheng ; Ardolino, Luke ; Evan, Carolyn P. ; Kaymakcalan, Marina ; Shaw, Grace K. ; Kantoff, Philip W. ; Taplin, Mary-Ellen ; Alimohamed, Nimira S. ; Joshua, Anthony M. ; Heng, Daniel Y.C. ; Sweeney, Christopher J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4362-f11f1951ca42e6603c2c6d5d5c01f467e2115a07b58f0074faddae6f15f3fd23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Abiraterone Acetate - administration & dosage</topic><topic>Abiraterone Acetate - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>AR targeting agents</topic><topic>Benzamides</topic><topic>CHAARTED</topic><topic>Disease-Free Survival</topic><topic>Docetaxel - administration & dosage</topic><topic>Docetaxel - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>mCRPC</topic><topic>mCRPC sequencing</topic><topic>mHSPC</topic><topic>Nitriles</topic><topic>Phenylthiohydantoin - administration & dosage</topic><topic>Phenylthiohydantoin - analogs & derivatives</topic><topic>Phenylthiohydantoin - therapeutic use</topic><topic>Prostatic Neoplasms, Castration-Resistant - drug therapy</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Francini, Edoardo</creatorcontrib><creatorcontrib>Yip, Steven</creatorcontrib><creatorcontrib>Ahmed, Shubidito</creatorcontrib><creatorcontrib>Li, Haocheng</creatorcontrib><creatorcontrib>Ardolino, Luke</creatorcontrib><creatorcontrib>Evan, Carolyn P.</creatorcontrib><creatorcontrib>Kaymakcalan, Marina</creatorcontrib><creatorcontrib>Shaw, Grace K.</creatorcontrib><creatorcontrib>Kantoff, Philip W.</creatorcontrib><creatorcontrib>Taplin, Mary-Ellen</creatorcontrib><creatorcontrib>Alimohamed, Nimira S.</creatorcontrib><creatorcontrib>Joshua, Anthony M.</creatorcontrib><creatorcontrib>Heng, Daniel Y.C.</creatorcontrib><creatorcontrib>Sweeney, Christopher J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical genitourinary cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Francini, Edoardo</au><au>Yip, Steven</au><au>Ahmed, Shubidito</au><au>Li, Haocheng</au><au>Ardolino, Luke</au><au>Evan, Carolyn P.</au><au>Kaymakcalan, Marina</au><au>Shaw, Grace K.</au><au>Kantoff, Philip W.</au><au>Taplin, Mary-Ellen</au><au>Alimohamed, Nimira S.</au><au>Joshua, Anthony M.</au><au>Heng, Daniel Y.C.</au><au>Sweeney, Christopher J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer</atitle><jtitle>Clinical genitourinary cancer</jtitle><addtitle>Clin Genitourin Cancer</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>16</volume><issue>2</issue><spage>130</spage><epage>134</epage><pages>130-134</pages><issn>1558-7673</issn><eissn>1938-0682</eissn><abstract>Although an androgen deprivation therapy plus docetaxel regimen was shown to extend the survival of some patients with metastatic hormone-sensitive prostate cancer compared with androgen deprivation therapy alone, currently, there is no report in the literature investigating the impact of upfront docetaxel on subsequent first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer. This study showed that their activity is maintained regardless of previous use of docetaxel for metastatic hormone-sensitive prostate cancer. These findings can aid treatment decision-making.
The CHAARTED (ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) and STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent therapies is still unexplored. As abiraterone acetate (AA) and enzalutamide (E) are the most commonly used first-line treatment for metastatic castration-resistant prostate cancer (mCRPC), we aimed to assess whether they maintained their efficacy after ADT+D versus ADT alone.
A cohort of patients with mCRPC treated between 2014 and 2017 with first-line AA or E for mCRPC was identified from 3 hospitals’ institutional review board-approved databases. Patients were classified by use of D for mHSPC. This time frame was chosen as ADT+D became a valid therapeutic option for mHSPC in 2014, and it inherently entailed a short follow-up time on AA/E. The endpoints included overall survival from ADT start, overall survival from AA/E start, and time to AA/E start from ADT start. Differences between groups were assessed using the log-rank test.
Of the 102 patients with mCRPC identified, 50 (49%) had previously received ADT alone, while 52 (51%) had ADT+D. No statistically significant difference in any of the evaluated outcomes was observed between the 2 cohorts. Yet, deaths in the ADT+D group were 12 versus 21 in the ADT alone, after a median follow-up of 24.4 and 29.8 months, respectively.
In a cohort of ADT/ADT+D-treated patients with mCRPC with short times to first-line AA/E and follow-up, the efficacy of AA/E is similar regardless of previous use of D.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29331381</pmid><doi>10.1016/j.clgc.2017.12.012</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-4270-7023</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1558-7673 |
| ispartof | Clinical genitourinary cancer, 2018-04, Vol.16 (2), p.130-134 |
| issn | 1558-7673 1938-0682 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5986287 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Abiraterone Acetate - administration & dosage Abiraterone Acetate - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use AR targeting agents Benzamides CHAARTED Disease-Free Survival Docetaxel - administration & dosage Docetaxel - therapeutic use Humans Male mCRPC mCRPC sequencing mHSPC Nitriles Phenylthiohydantoin - administration & dosage Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - therapeutic use Prostatic Neoplasms, Castration-Resistant - drug therapy Retrospective Studies Survival Analysis Treatment Outcome |
| title | Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T03%3A05%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Outcomes%20of%20First-line%20Abiraterone%20Acetate%20or%20Enzalutamide%20for%20Metastatic%20Castration-resistant%20Prostate%20Cancer%20After%20Androgen%20Deprivation%20Therapy%C2%A0+%20Docetaxel%20or%20ADT%20Alone%20for%20Metastatic%20Hormone-sensitive%20Prostate%20Cancer&rft.jtitle=Clinical%20genitourinary%20cancer&rft.au=Francini,%20Edoardo&rft.date=2018-04-01&rft.volume=16&rft.issue=2&rft.spage=130&rft.epage=134&rft.pages=130-134&rft.issn=1558-7673&rft.eissn=1938-0682&rft_id=info:doi/10.1016/j.clgc.2017.12.012&rft_dat=%3Cproquest_pubme%3E1989592559%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1989592559&rft_id=info:pmid/29331381&rft_els_id=S1558767317303981&rfr_iscdi=true |